NCT00902187已完成1 期
An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- AUCinf, AUClast, and Cmax of 5-HMT
研究概览
简要总结
To demonstrate bioequivalence of fesoterodine 4 mg tablets manufactured at Vega Baja, versus Zwickau.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
排除标准
- •Subjects with evidence or history of clinically significant urologic diseases
- •A positive urine drug screen
- •Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method
研究组 & 干预措施
Reference
Other
fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
干预措施: Fesoterodine (Drug)
Test
Other
fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
干预措施: Fesoterodine (Drug)
结局指标
主要结局
AUCinf, AUClast, and Cmax of 5-HMT
时间窗: 6 weeks
次要结局
- Safety laboratory tests and adverse events(6 weeks)
- Tmax and half-life of 5-HMT as data permit(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy VolunteersHealthyNCT01508195Janssen Research & Development, LLC64
已完成
1 期
A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy VolunteersHealthyNCT01508182Janssen Research & Development, LLC64
已完成
1 期
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy VolunteersHealthyNCT01454622Johnson & Johnson Pharmaceutical Research & Development, L.L.C.64
已完成
1 期
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy VolunteersHealthyNCT01518712Johnson & Johnson Pharmaceutical Research & Development, L.L.C.64
已完成
1 期
A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy VolunteersHealthyNCT01463228Janssen Research & Development, LLC83